Beximco Pharmaceuticals Ltd - Dhaka-based generic pharmaceutical products and active pharmaceutical ingredients maker - Clarifies recent press report that discussed findings from a planned good manufacturing procedure inspection of the company's ophthalmic manufacturing unit between July 28 and August 1 by The Malta Medicines Authority.
As noted in the press report, the inspection audit cites one critical issue, three major deficiencies and a number of other deficiencies. Points out it does not currently export ophthalmic products from this manufacturing unit to the EU or the European Economic Area. Further, while the MMA has proposed that the EU prohibits the company from exporting these products to the EU or EEA , this proposal has not yet been ratified by the EU. In addition, firm continues to supply these products to other markets where approvals have been received.
Adds sales from the plant totalled less than 1% of group total in last reported financial year to June 30, 2022. Working closely with the MMA to remedy the situation, the costs of which will not have a material financial impact.
Current stock price: 38.01 pence
12-month change: down 49%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Beximco Pharma (BXP)